Linagliptin and Mesenchymal Stem Cells: A Pilot Study

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 2, 2015

Primary Completion Date

March 2, 2018

Study Completion Date

March 2, 2018

Conditions
Schizophrenia
Interventions
DRUG

Linagliptin

12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.

Trial Locations (1)

89503

University of Nevada School of Medicine, Reno

All Listed Sponsors
collaborator

Augusta University

OTHER

lead

University of Nevada, Reno

OTHER

NCT02442817 - Linagliptin and Mesenchymal Stem Cells: A Pilot Study | Biotech Hunter | Biotech Hunter